SEC Form EFFECT filed by ABVC BioPharma Inc.
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | August 1, 2024 |
Accession Number: | 0001013762-24-001634 | ||||||
Submission Type: | POS AM | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | August 1, 2024 |
Accession Number: | 0001013762-24-001634 | ||||||
Submission Type: | POS AM | ||||||
|
8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
424B4 - ABVC BIOPHARMA, INC. (0001173313) (Filer)
SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)
SC 13G - ABVC BIOPHARMA, INC. (0001173313) (Subject)
SC 13D - ABVC BIOPHARMA, INC. (0001173313) (Subject)
3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)
3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)
3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)
FREMONT, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan. The acquisition of real estate assets, estimated at approximately $2.96 million via an equity transfer of $3.50 per share, is to develop plant factories for ABVC's botanical pipeline strategically; ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pha
• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents and FDA Approvals FREMONT, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the second quarter ended June 30, 2024. Key Financial and Operational Highlights: 1. Significant Global Licensing Agreements: - Vitargus® Licensing: Along with
USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 15, 2024 /PRNewswire/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can accurately detect early-stage pancreatic cancer with 97% accuracy. According to Johns Hopkins Medicine, up to 10% of patients who receive an early diagnosis become disease-free after treatment, meaning the earlier it's detected, the better the patient's chances to survive. The American Cancer Society estimates that about 66,440 people (34,530 men and 31,910 women) will be diagnosed with pancreatic cancer in the USA this year, projec
FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry. The acquisition includes Malaysian Import Trading Company, Direct Sales Company, and Taiwanese Direct Sales Company, which are estimated to be approximately equivalent to $8.33M. AiBtl purchased 100% shares of TT Life by swapping its 1.66M shares at $5 per share. This strategic mov
- SEC Filing
https://www.sec.gov/ix?doc=/Archives/edgar/data/1173313/000121390024041053/ea0205569-8k_abvcbio.htm
Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply in today's pre-market trading following first-quarter results. Tesla posted weaker-than-expected earnings and sales results for its first quarter on Tuesday. The electric vehicle giant also announced plans to speed up the launch of new models. Tesla shares jumped 10.6% to $160.01 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:CSSE) shares gained 49.4% to $0.2276 in pre-market trading after gaining over 8% on Tuesday. Zapata Computing Holdings Inc. (NASDAQ:ZPTA) gained 30.8% to $2.04 in pre-market trading after declining 10% on Tues
FREMONT, CA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a global licensing definitive agreement with AiBtl BioPharma Inc. (AiBtl) for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the "Licensed Products"). The agreement has the potential of licensing income worth $467M and royalties up to $200M. The Licensed Products for MDD and ADHD, owned by ABVC and its su
FREMONT, CA, June 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the appointment of Dr. Uttam Yashwant Patil (Dr. Uttam) as the new Chief Executive Officer (CEO). Dr. Uttam is very familiar with ABVC and their subsidiaries, because of his role as Chief Operating Officer & Chief Scientific Officer of BioKey, Inc., a GMP-certified facility owned by ABVC that provides its clients with integrated pharmaceutical services, including early-phase product development, formulation development, analytical development & d